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Abstract
Background/aim In order to define future chemoprevention
strategies for adenomas or carcinomas in the pouch of
patients with familial adenomatous polyposis (FAP), a 4-
weeks intervention with (1) sulindac, (2) inulin/VSL#3, and
(3) sulindac/inulin/VSL#3 was performed on 17 patients
with FAP in a single center intervention study.
Primary endpoints were the risk parameters cell prolifera-
tion and glutathione S-transferase (GST) detoxification
capacity in the pouch mucosa; secondary endpoints were the
short chain fatty acid (SCFA) contents, pH, and cytotoxicity
of fecal water.
Methods Before the start and at the end of each 4-week
intervention period, six biopsies of the pouch were taken
and feces was collected during 24 h. Cell proliferation and
GST enzyme activity was assessed in the biopsies and pH,
SCFA contents, and cytotoxicity were assessed in the fecal
water fraction. The three interventions (sulindac, inulin/
VSL#3, sulindac/inulin/VSL#3) were compared with the
Mann–Whitney U test.
Results Cell proliferation was lower after sulindac or
VSL#3/inulin, the combination treatment with sulindac/
inulin/VSL#3 showed the opposite. GST enzyme activity
was increased after sulindac or VSL#3/inulin, the combi-
nation treatment showed the opposite effect. However, no
significance was reached in all these measures. Cytotoxicity,
pH,andSCFAcontentoffecalwatershowednodifferencesat
all among the three treatment groups.
Conclusion Our study revealed non-significant decreased
cell proliferation and increased detoxification capacity after
treatment with sulindac or VSL#3/inulin; however, com-
bining both regimens did not show an additional effect.
Keywords Familial adenomatous polyposis.Sulindac.
Inulin.VSL#3.Cell proliferation
Introduction
Familial adenomatous polyposis (FAP) is an inherited autoso-
mal dominant disease with an estimated prevalence of 0.02%.
ItiscausedbyamutationoftheAPCgeneandischaracterized
by the progressive development of hundreds to thousands of
adenomatous polyps in the large intestine, in the second or
third decade of life [1]. The prevalence of ileal adenomas is
a s s u m e dt ob e9 %t o2 0 %[ 2], but the occurrence of ileal
carcinoma is rare. To eliminate the risk of colorectal cancer in
patients with FAP, a prophylactic (procto) colectomy with an
ileo-rectal anastomosis or an ileal pouch anal anastomosis
(IPAA) is the treatment of choice [3].
Despite of resecting all colonic mucosa, adenomas occur
in the pouch with a reported incidence of 35% to 75% after
a follow-up of at least 5 years [4–9]. If the adenoma-
carcinoma sequence in the pouch is the same as in the
colon, which takes approximately 20 years, a rise in pouch
carcinomas could well be expected in the near future. So
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has been described [9–14].
After an IPAA procedure, colonic metaplasia of the
ileal mucosa of the pouch occurs in the form of villous
atrophy, crypt hyperplasia, and an increased excretion of
mucin [15–17].
In the pouch, there is also an increase in anaerobic
bacteria [18, 19], leading to more deconjugation and
dehydroxylation of bile acids [19], whereas an increase in
short chain fatty acids (SCFA) to colonic levels is also
observed [20]. Such changes may influence the balance
between cell proliferation and apoptosis, which is disturbed
in colorectal cancer [21]. We recently showed that after
construction of an IPAA, cell proliferation in the ileal pouch
was increased as compared to the levels of the afferent ileal
loop [22].
The effect of intraluminal components on apoptosis,
cell proliferation, and differentiation is complex. Depend-
ing on the models used, SCFA like butyrate can enhance
or decrease mucosal proliferation [23–25]. Butyrate can
also induce apoptosis, which is strongly down-regulated in
FAP [26, 27]. Secondary de-conjugated bile acids like
deoxycholate and chenodeoxycholate may stimulate cell
proliferation [28], apoptosis [29], and cyclooxygenase-2
[30] (COX-2), which is strongly over-expressed in
colorectal cancer [31]. Thus, luminal components may be
responsible for alterations in mucosal cell kinetics, and
measurement of the cytotoxicity of the fecal water could
indicate the presence of damaging constituents in the
pouch [32].
Mucosal factors may also contribute to the adenoma and
carcinoma risk. Mucosal protective systems such as the
glutathione S-transferases (GSTs) are expressed along the
human intestine, with much higher levels in the ileum than
in the colon [33]. GSTs are a class of enzymes that are
pivotal in the detoxification of carcinogens. An inverse
correlation between the GST enzyme activity in the mucosa
of the gastrointestinal tract and the tumor incidence has
been demonstrated [34]. The GST enzyme activity is down-
regulated during colonic metaplasia in the pouch of patients
with FAP [35], which is in line with the much lower GST
enzyme contents generally found in colon as compared to
small intestinal tissue [33, 36].
Non steroidal anti-inflammatory drugs (NSAIDs) are
potential agents for the chemoprevention of colorectal
cancer. They inhibit both COX-1 and COX-2, which are
enzymes involved in prostaglandin synthesis. There is
strong evidence that COX-2 expression is associated with
colorectal cancer [37]. In patients with FAP, COX-2
expression is also elevated [38]. Chemoprevention trials
with NSAIDs have shown both a reduction in number and
size of colorectal adenomas in patients with FAP [39, 40].
Sulindac has been approved by the Food and Drug
Administration as an adjunct in the treatment of FAP.
Although the chemoprevention by NSAIDs is promising,
the adenoma regression is only partly and temporarily,
whereas adenomas with low COX-2 expression may be
resistant to NSAIDs [41].
Therefore, it would be worthwhile to combine NSAIDs
with other chemopreventive agents such as pre- or pro-
biotics. These so called “nutriceuticals” may induce a flora
which is capable of decreasing bile acid concentrations,
enhancing formation of SCFA such as butyrate and
reducing intestinal pH [42]. Butyrate is able to cause
apoptosis and to protect against carcinogens by enhancing
expression of mucosal detoxification enzymes such
as glutathione S-transferases [43]. Lactic acid-producing
bacteria such as Bifido bacteria or Lactobacilli are the most
widely studied probiotics with potential cancer protective
effects, whereas intestinal exposure to pre/probiotics can
occur via oral intake [44, 45]. VSL#3, a mixture of four
Lactobacilli, three Bifidum, and one Streptococcus species,
has shown beneficial effects on pouchitis in patients with
ulcerative colitis (UC) [46, 47]. In vivo studies with VSL#3
in rats showed a decrease of colonic cell proliferation [48].
Moreover, inulin can inhibit cell proliferation and induce
a p o p t o s i si nv i t r o[ 49], both features which are disturbed
in FAP. We earlier demonstrated that bacterial fermenta-
tion of orally ingested fructooligosaccharides, a type of
inulin, or resistant starch, occurs in patients with an IPAA
[50].
The purpose of this intervention study is to investigate
whether short-term modulation of luminal or mucosal
factors in the pouch of patients with FAP is possible by
NSAID (sulindac) monotherapy, combination of pre- and
probiotics (inulin/VSL#3), and the combination of both
these intervention regimens (sulindac/inulin/VSL#3).
Material and methods
Patients and interventions
Patients with FAP and an IPAA, who were under
surveillance at the Department of Gastroenterology of the
Radboud University Nijmegen Medical Centre or regional
affiliated hospitals, were invited to participate in this study.
Seventeen patients with FAP were included in the period
May 2006–July 2006. The diagnosis FAP was based on
either a clinical presentation of at least 100 colonic
adenomas or presence of a mutation in the APC gene.
A randomized pilot study with sulindac monotherapy
(300 mg/day; 1 tablet of 100 mg in the morning and two
tablets in the evening), combination therapy with VSL#3
(9×10
11 bacteria/day) and inulin (12 g/day), or the
combination of sulindac and VSL#3/inulin was performed
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provided by Sigma-Tau BV, Utrecht, the Netherlands.
VSL#3 was mixed with some yoghurt and taken in the
evening. VSL#3 contains Streptococcus thermophilus, three
strains of Bifidobacteria (Bifidobacterium breve, Bifidobac-
terium longum, Bifidobacterium infantis) and four strains of
Lactobacilli (Lactobacillus acidophilus, Lactobacillus plan-
tarum, Lactobacillus casei, and Lactobacillus bulgaricus).
Inulin (Frutafit® IQ) was provided by Sensus, Roosendaal,
the Netherlands, and it was taken two times a day in sachets
of 6 g each. Study participants were instructed to consume
their normal home diet during the course of the study.
Inclusion criteria: male and female patients between 18
and 70 years of age and diagnosed with familial adenoma-
tous polyposis, with an ileal pouch anal anastomosis
(IPAA). Exclusion criteria were: known allergy to the study
medication, prior gastric or intestinal ulcer, history or other
evidence of severe illness, malignancy or any other
condition which makes the patient unsuitable for the study,
women with ongoing pregnancy or breast feeding, chronic
liverdiseaseorchronicrenaldisease,serumcreatininlevel>1.5
times the upper limit of normal, history of severe allergy,
history of symptomatic and/or significant cardiovascular
disease.
The study was approved by the regional (Arnhem/
Nijmegen) medical ethical review committee (CMO no.
2002/111), and informed consent was obtained from all
patients.
Luminal factors
Feces was collected on dry ice in separate portions during
24 h, on the day before endoscopy. It was transported to the
laboratory on dry ice and was subsequently stored at −20°C
until processing. The thawed portions of feces were
weighed, added together, and homogenized with a blender.
Next, the pH of the feces was measured at room
temperature (pH meter PHM 82, Radiometer, Copenhagen,
Denmark). Fecal water was prepared by centrifugation of a
portionofthehomogenizedfecesat150,000×g for 1 h at 4°C.
Fecal water was filtered through a 0.20-μm filter (Schleicher
& Schuell, Dassel, Germany), and it was stored in small
portions at −20°C until further analysis.
Short chain fatty acids in fecal water fractions were
determined as described before [50].
Cytotoxicity of the fecal water was measured as
described before [32], with slight modifications. In short,
HT29 cells were seeded at a density of 15,000 cells/well in
flat-bottomed 96 wells plates (Costar, Corning Incorporated,
Corning,NY,USA).TheHT29cellswereallowedtogrowfor
24 h in PC-1 culture medium (Lonza, Verviers, Belgium),
culture medium was removed, and the cells were incubated
with200 μl testsampleand controls. PC-1mediumalone was
used as a negative control and PC-1 medium containing
3.2 mM unconjugated deoxycholic acid (Sigma, St Louis,
USA) was used as a positive control for cytotoxicity. Wells
without cells served as background correction in the measure-
ments. Fecal water diluted in PC-1 medium was added to the
wells in the following dilutions:2, 4,8, etc., until 1,024 times.
Every dilution was measured in octuple. After incubating for
24 h, the medium was removed and new PC-1 medium
containing 10% (v/v) proliferation reagent WST-1 (Roche,
Penzberg, Germany) was added to each well. In viable cells,
WST-1 will be converted to formazan by mitochondrial
activity. After 2 h, the color intensity of the formazan formed
wasquantifiedinamicroplatereader(Thermomax,Molecular
Devices, Sopachem B.V., Wageningen, the Netherlands). The
absorbance was measured against the background controls at
a wavelength of 405 nm and a reference wavelength of
620 nm. The cell viability was expressed as the percentage of
absorption of test samples, as compared with that of wells
incubated with medium alone. Results are expressed as the
dilution factors of the fecal water at which 50% of the cells do
survive.The mean value ofthree independent experiments for
each sample is given.
Mucosal factors
Before endoscopy, patients were fasted overnight. On the
day of examination, patients were encouraged to drink
liberally. No laxatives or cathartic enemas were given. To
clear the pouch of fecal ruminants, two 250 ml water
enemas were given prior to endoscopy.
Six biopsies were taken at random locations from the
pouch mucosa, at least 5 cm proximal from the anal verge.
Two biopsies were stretched on filter paper to maintain a
correct orientation of crypts, biopsies were subsequently
fixated in formalin and embedded in paraffin. Four biopsies
were frozen in liquid nitrogen and stored at −80°C until
use.
Cell proliferation was measured by immunohistochemistry
in the stretched formalin-fixated biopsies exactly as described
by usbefore[22]. The cell proliferation activity was assessed
after staining with the monoclonal antibody MIB-1 (Dako A/
S, Glostrup, Denmark), which recognizes the Ki-67 nuclear
antigen. Evaluation of immunostaining results was done
Week                 1             2            3            4             5            6            7            8       
Collection of biopsies
Collection of feces           x
Randomisation
Sulindac + Inulin/VSL#3
(Group 3)
Sulindac + Inulin/VSL#3
(Group 3)
Inulin/VSL#3
(Group 2)
Sulindac
(Group 1)
x
x
x
x
x
Fig. 1 Study design
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patient. For evaluation of MIB-1 immunostained tissue
sections, crypts whose entire length could be visualized
were photographed under 400× magnification using a Zeiss
KS400 computer-aided system. Crypts were excluded if they
did not reach the muscularis mucosae or had multilayered
bases. MIB-1 positivity was identified as brown nuclear
staining. The number of MIB-1 positive epithelial cells and
the total number of epithelial cells in up to five crypts per
tissue section were counted from the screen. The labeling
index for each crypt was given by the ratio of MIB-1
positive cells over the total number of crypt epithelial cells.
For each patient, the labeling index was expressed as means
of three to five counted crypts. If less than three crypts could
be evaluated, the patient was excluded from analysis.
Four biopsies were thawed, pooled, homogenized, and
glutathione S-transferase enzyme activity with 1-chloro,2,4-
dinitrobenzene as substrate was assayed as described before
[33].
Statistical analyses
Statistical analyses were performed with SPSS statistical
software, version 16.0 (SPSS Inc, Chicago, Illinois, USA).
Frequency tables were provided describing patient baseline
characteristics. Pearson's chi-squared test was used to
compare categorical variables. Fisher's exact test was used
where appropriate. Continuous variables were compared
with Mann–Whitney U test.
Outcomes data were then pooled, and the difference
between post- and pre-intervention was plotted (using
Prism Graphpad) and compared between three interventions
using Mann–Whitney U analyses. A two-sided p value of
<0.05 was considered statistically significant.
Results
Seventeen patients with FAP, all having an IPAA (median
age of the pouch 13, range 1–21 years), started the study
protocol (Fig. 1). Some baseline characteristics of these
patients are given in Table 1.
One patient, who started with sulindac monotherapy,
developed an antral bleeding after 2 days of sulindac use
and stopped medication. This patient agreed to continue the
study 4 weeks later, than receiving VSL#3/inulin for
4 weeks, a regimen that was finished without further
complications. Two patients did not finish one intervention
period for reasons not associated with side effects: one
patient who started with VSL#3/inulin, stopped during the
second regimen (combination of sulindac/VSL#3/inulin),
whereas another patient did not complete the first VSL#3/
inulin regimen, but did successfully complete the combi-
nation regimen. Summarizing, seven patients successfully
completed the intervention with sulindac monotherapy, nine
patients completed the intervention with VSL#3/inulin, and
15 patients completed the intervention with the combina-
tion of sulindac/VSL#3/inulin (see Table 1).
Primary endpoints were cell proliferation and GSTenzyme
activity (mucosal factors), secondary endpoints were short
chain fatty acid (SCFA) contents, pH, and cytotoxicity of the
fecal water (luminal factors). The primary data of these
p r i m a r ya n ds e c o n d a r ye n d p o i n t s ,a sm e a s u r e di nb i o p s i e s
and feces of the patients, are given in Table 2.T h ec e l l
proliferation rates before and after the intervention period
were compared within each patient, and the differences in cell
proliferation, post-intervention minus pre-intervention values,
are given in Fig. 2. Although median cell proliferation values
are down-regulated in the sulindac and VSL#3/inulin groups,
this was not seen in the combination group. Overall, no
significant differences were observed (P=0.13).
For GST enzyme activity (Fig. 3), a similar pattern was
observed: median GST enzyme activities are up-regulated
in the sulindac and VSL#3/inulin groups but not in the
combination group. Overall, no significant differences were
observed (P=0.16).
For the secondary endpoints, cytotoxicity, pH, and
concentrations of SCFA in the fecal water (see Figs. 4, 5,
and 6) no significant differences were also observed in the
post-treatment vs. pre-treatment values (P values of 0.19,
0.64, and 0.98 for cytotoxicity, pH, and concentrations of
SCFA, respectively).
Discussion
Although both the pouch and its afferent loop contain the
same pre-existing ileal mucosa, adenomas occur more
Table 1 Patient characteristics
Variable Group 1 (sulindac) Group 2 (VSL#3/inulin) Group 3 (sulindac+VSL#3/inulin)
Number 7 9 15
Males/females 4/3 6/3 10/5
Median age (range) in years 36 (19–63) 38 (18–53) 38 (18–63)
Median age pouch (range) in years 10 (3–21) 16 (1–21) 13 (1–21)
578 Int J Colorectal Dis (2011) 26:575–582frequently in the pouch of patients with FAP, suggesting
an accelerated adenoma formation in the pouch [5–8].
Previously, we demonstrated in patients with FAP that cell
proliferation was significantly higher in the pouch mucosa
than in the mucosa of the afferent ileal loop, which could
partly explain the higher adenoma and carcinoma rates in
the pouch [22]. Several studies indicated that cell prolifera-
tion of normal-appearing colorectal mucosa of patients with
adenomas or carcinomas was 19% to 86% higher compared
to colorectal mucosa of healthy persons [51, 52]. These
findings strongly suggest an association between the
presence of adenomas or carcinomas and an increased
mucosal cell proliferation. In addition, intestinal epithelial
cell proliferation in patients with FAP is very high [53, 54]
which stresses the need for studies on lowering the cell
proliferation in these patients. Intraluminal changes that
occur after construction of the pouch, such as changes in
bacterial flora, bile acid composition, concentration of
SCFA, pH, etc., can explain the higher cell proliferation in
the pouch mucosa in comparison to mucosa of the afferent
ileal loop. Therefore, in this study, we focused to improve
short time risk parameters both from mucosal (cell prolifera-
tion, mucosal GST defense against toxins/carcinogens) as well
as luminal (cytotoxicity, pH, and concentrations of SCFA)
origin. We did choose for a short intervention period of
4 weeks, since we focused on the mucosa of the human
intestine, which is renewed every 3–4d a y s[ 55]a n do ns o m e
luminal factors present in the fecal water, which may have
even shorter half-lives.
Since sulindac has been proved effective in reducing the
number and size of colon adenomas in patients with FAP
[39], in short time experiments, we expected a reduction of
cell proliferation as an important factor in the formation of
adenomas or carcinomas. Median cell proliferation rates are
somewhat reduced; however, no significance is reached in
the sulindac and VSL#3/inulin groups. This tendency,
however, is not seen in the combination group (sulindac+
VSL#3+inulin). Exactly the same favorable tendency is
seen for the GST detoxification activity in the pouch
mucosa: after treatment with sulindac or VSL#3/inulin,
there is an increase in median GST activity, which is not
further elevated in the combination group. Again, however,
results did not reach statistical significance. With respect to
Table 2 Median (range) values of the endpoint parameters
Endpoint parameter Baseline Group 1 (sulindac) Group 2 (VSL#3+inulin) Group 3 (sulindac+VSL#3+inulin)
Proliferation
a 0.51 (0.35–0.80) 0.47 (0.15–0.65) 0.42 (0.39–0.55) 0.60 (0.39–0.75)
GST
a 376 (271–606) 421 (334–523) 382 (328–563) 399 (229–518)
Cytotoxicity
a 54.2 (11.7–325) 95.0 (20.8–150) 50.8 (1.5–237) 95.0 (20.0–177)
SCFA
a 77.2 (42.1–118) 71.9 (51.4–121) 67.8 (31.2–138) 77.8 (42.1–102)
Fecal pH
a 5.92 (4.90–7.37) 5.48 (4.82–7.22) 6.05 (4.82–6.96) 5.53 (4.86–6.59)
Proliferation is given as the ratio labeled/unlabeled cells. GST activity is given in nanomoles per minute milligram protein. Cytotoxicity is the
dilution factor at which 50% of the cells have died. SCFA is given in millimoles per liter. Fecal pH is given in pH units
aValues are given as median (range)
Fig. 2 For each patient, the difference in cell proliferation at the end
of the intervention period, minus cell proliferation at start, was
calculated. Median differences (solid line in each bar) in cell
proliferation are given for each intervention group. Bars represent
25% and 75% percentiles, and the minimum and maximum differ-
ences are also indicated (T bar). Number of patients involved are:
sulindac, n=7, VSL#3+inulin, n=9, sulindac+VSL#3+inulin
(combi), n=14, P value (Kruskal–Wallis)=0.13
Fig. 3 For each patient, the difference in GST enzyme activity at the
end of the intervention period, minus GST enzyme activity at start,
was calculated. Median differences (solid line in each bar) in GST
enzyme activity are given for each intervention group. Bars represent
25% and 75% percentiles, and the minimum and maximum differ-
ences are also indicated (T bar). Number of patients involved are:
sulindac, n=7, VSL#3+inulin, n=9, sulindac+VSL#3+inulin
(combi), n=15, P value (Kruskal–Wallis)=0.16
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activity, we can conclude that there may be a positive effect
(lowering of cell proliferation and increase of GST enzyme
activity) of sulindac monotherapy and treatment with
VSL#3/inulin, but surprisingly, when both regimens are
combined, no additive effect is achieved. Based on these
results, we can elaborate on the suspected number of
patients that need to be included. For example, using the
mean GST activity in the sulindac monotherapy group
versus the VSL#3/inulin group, a sample size of 67 patients
with FAP in each group is needed to detect a probability of
0.64 that an observation in the sulindac group is less than in
the VSL#3/inulin group, using a Mann–Whitney U test
with a 0.05 two-sided significance level and 80% power.
For the luminal parameters measured in this study, the
results more clearly indicate that no effect on fecal pH,
SCFA content in fecal water, and to a lesser extent on the
cytotoxicity has to be expected from any intervention
regimen applied in this study. From sulindac monotherapy,
hardly any effect on SCFA and pH was expected. However,
the VSL#3/inulin arm was included to provoke an effect on
both these parameters, since inulin, with the help of the
eight different strains of Lactobacilli and Bifidobacteria in
VSL#3, was expected to be degraded into SCFA in the
pouch [50], which subsequently could have a lowering
effect on the pH. Our data, however, seem to indicate that
absolutely no effect on pH and SCFA can be expected even
after scaling up the study. This is in contrast with the results
of Welters et al. [56] who clearly demonstrated fermenta-
tion of inulin in the pouch of patients with ulcerative colitis.
This might be explained either by the difference in dose of
inulin (24 vs. 12 g daily in our study) or by the different
characteristics of pouches in patients with FAP as compared
to patients with UC. Duffy et al. [57] found differences in
bacterial colonization in pouches of patients with UC and
FAP and they speculated that pouch inflammation, which is
frequently seen in UC, might be associated to this finding.
Furthermore, inhibition of inulin fermentation by VSL#3
seems highly unlikely since inulin is bifidogenic [58] and
Bifidobacteria are a main component of VSL#3.
To our knowledge, this is the first intervention study on
patients with FAP having an IPAA, which is a strength of
this study. Moreover, since APC mutations are main
contributing events in colorectal carcinogenesis in general,
studies performed in patients with FAP, where colon
carcinogenesis is highly accelerated, might provide insight
in (chemo) prevention of sporadic colorectal cancer.
However, since FAP is a rare disorder, it is difficult to
study in a single center fashion, even in our center which is
specialized in hereditary colorectal cancer. The main
Fig. 5 For each patient, the difference in total SCFA concentrations in
fecal water at the end of the intervention period, minus total SCFA
concentrations at start, was calculated. Median differences (solid line in
each bar) in total SCFA concentrations in fecal water are given for each
intervention group. Bars represent 25% and 75% percentiles, and the
minimum and maximum differences are also indicated (Tb a r ). Number
of patients involved are: sulindac, n=7, VSL#3+inulin, n=9, sulindac+
VSL#3+inulin (combi), n=15, P value (Kruskal–Wallis)=0.98
Fig. 4 For each patient, the difference in cytotoxicity of fecal water at
the end of the intervention period, minus cytotoxicity at start, was
calculated. Median differences (solid line in each bar) in cytotoxicity
are given for each intervention group. Bars represent 25% and 75%
percentiles, and the minimum and maximum differences are also
indicated (T bar). Number of patients involved are: sulindac, n=7,
VSL#3+inulin, n=9, sulindac+VSL#3+inulin (combi), n=15,
P value (Kruskal–Wallis)=0.19
Fig. 6 For each patient, the difference in fecal pH at the end of the
intervention period, minus fecal pH at start, was calculated. Median
differences (solid line in each bar) in fecal pH are given for each
intervention group. Bars represent 25% and 75% percentiles, and the
minimum and maximum differences are also indicated (Tb a r ). Number
of patients involved are: sulindac, n=7, VSL#3+inulin, n=9, sulindac+
VSL#3+inulin (combi), n=15, P value (Kruskal–Wallis)=0.64
580 Int J Colorectal Dis (2011) 26:575–582weakness of this study therefore is the small number of
patients included in the study.
In conclusion, in addition to the advantageous effect on
adenomas as reported before for sulindac, we investigated
whether additional or additive positive effects could be
achieved on some risk parameters by trying to modulate
both mucosal and luminal factors. However, we did not find
an indication that the combination of VSL#3/inulin/sulin-
dac could add anything for the chemoprevention of
adenomas in patients with FAP, in comparison with
sulindac alone.
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